EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma

Dev Kashyap, Manish Kumar, Ayush Singh, Arnav Kansal, Amanpreet Kaur, Shruti Srivastava, Vipin Saini, Jagpreet Kour

Expert Review of Anticancer Therapy · 02.01.2026 · 26 (1) · 81-92

DOI: 10.1080/14737140.2025.2575017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Anticancer Therapy, online erschienen am 14.10.2025. Verfasst von Dev Kashyap und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quality Assurance, ISF College of Pharmacy, Moga, India. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hepatocellular carcinoma (HCC), a common and aggressive liver cancer, frequently manifests at an advanced stage, restricting the effectiveness of standard treatments. Recent advancements in nanotechnology, particularly in liposome-based delivery systems, offer promising approaches to enhance treatment efficacy and immunological regulation in hepatocellular carcinoma (HCC). AREAS COVERED: This study emphasizes the diverse functions of liposomes in augmenting drug solubility, targeting neoplastic tissues, increasing immunological responses, and surmounting biological barriers. It investigates the synergy of liposomal platforms and immunotherapies, including checkpoint inhibitors, and their incorporation with locoregional treatments for advanced-stage hepatocellular carcinoma (HCC). EXPERT OPINION: Liposomes are a revolutionary approach in cancer immunotherapy. Innovations like PEGylation, surface ligand modification, and dual-drug encapsulation have significantly enhanced treatment outcomes in preclinical and early clinical contexts. Advancements, especially in patient-specific and stimuli-responsive systems, may transform the future of HCC care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapyHumansLiposomesAnimalsDrug Delivery SystemsNanotechnologyImmune Checkpoint InhibitorsNeoplasm Staging

Stichwörter der Autor:innen

Drug deliveryHepatocellular cancerImmunotherapyLiposomesNanotechnology

Substanzen

LiposomesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Quality Assurance, ISF College of Pharmacy, Moga, India.
  • Department of Pharmaceutics, ISF College of Pharmacy, Moga, India.
  • Department of Pharmacy, ISF College of Pharmacy, Moga, India.
  • Department of Pharmaceutics, School of Pharmacy, Chandigarh University, Unnao, U.P, India.
  • Department of Pharmaceutics, MM College of Pharmacy, MM(DU), Ambala, India.
  • Gurukul Institute of Pharmaceutical Sciences, Fatehgarh Sahib, India.

Zitieren

APA

Kashyap, D., Kumar, M., Singh, A., Kansal, A., Kaur, A., Srivastava, S., Saini, V., & Kour, J. (2026). Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma. Expert Review of Anticancer Therapy, 26(1), 81-92. https://doi.org/10.1080/14737140.2025.2575017

Vancouver

Kashyap D, Kumar M, Singh A, Kansal A, Kaur A, Srivastava S, et al. Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma. Expert Review of Anticancer Therapy. 2026;26(1):81-92. doi:10.1080/14737140.2025.2575017

BibTeX
@article{Kashyap2026,
  author = {Kashyap, Dev and Kumar, Manish and Singh, Ayush and Kansal, Arnav and Kaur, Amanpreet and Srivastava, Shruti and Saini, Vipin and Kour, Jagpreet},
  title = {Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma},
  journal = {Expert Review of Anticancer Therapy},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {81--92},
  doi = {10.1080/14737140.2025.2575017}
}
Kostenlos starten →